TheraRadar
← Back
Data updated: Jun 28, 2026

ASPEN AIR

Pharma
Pharmaceuticals

ASPEN AIR is a pharmaceutical company with 2 FDA-approved products.

2013
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

ASPEN AIR's Key Drugs

ASPEN AIR's core commercial portfolio centers on NITROGEN, NF, OXYGEN, USP — its most strategically important drugs approved in the last 15 years.

NITROGEN, NF
Other
Approved 2013
OXYGEN, USP
Respiratory
Approved 2013

ASPEN AIR's Recent FDA Approvals

New NDA/BLA approvals for ASPEN AIR over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ASPEN AIR's Therapeutic Areas

Disease areas where ASPEN AIR has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

ASPEN AIR Pipeline Snapshot

Active clinical trials for ASPEN AIR across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • NITROGEN, NF leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling